SVB Securities lowered the firm’s price target on Veradigm to $17 from $24 and keeps an Outperform rating on the shares. The firm notes shares were under pressure on a press release acknowledging a failure in internal controls around revenue recognition for the past six quarters. In conjunction with the announcement, the company cut its full year 2023 guidance by about $15M in revenues and 10c on EPS, reflecting similar growth rates but on a lower baseline for 2022. SVB expects a meaningful pullback in shares as this introduces a sharp counterpoint to Veradigm’s "steady and reliable earnings/FCF" investment thesis. However, the firm leaves its forward outlook unchanged and sees the re-based level presenting a potentially attractive entry point after pullback.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MDRX:
- Veradigm cuts FY23 EPS view to 80c-90c from 90c-$1.00, consensus 96c
- Veradigm discloses internal control failures on revenue recognition, delays 10-K
- Veradigm, HealthVerity team on research and care for patients with CVD
- Veradigm downgraded to Neutral from Overweight at Piper Sandler
- Piper Sandler healthcare tech analysts to hold analyst/industry conference call